Aashka Hospitals Ltd.

74.99 -0.51 ▼-0.7%

06 May 2024, 04:01:00 PM
Volume: 6,000

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Industry Icon Hospital & Healthcare Services Compare with Industry peers
Website http://www.aashkahospitals.in
Market Cap 175.48 Cr.
Enterprise Value(EV) 200.51 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -1.10 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-03
Industry PE 67.25 Trailing Twelve Months Ending 2023-03
Book Value / Share 40.15 Trailing Twelve Months Ending 2023-03
Price to Book Value 1.87 Calculated using Price: 74.99
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 2.34 Cr. 23,400,000 Shares
FaceValue 10
About Aashka Hospitals Ltd.
Aashka Hospital is an integrated healthcare service provider that offers the best quality of healthcare facilities including prevention, best treatment, and rehabilitation.

Aashka Hospitals Ltd. Delivery

Delivered Qty
Traded Qty

Aashka Hospitals Ltd. Performance

1 Day
-0.68%
1 Week
-4.65%
1 Month
-2.61%
3 Month
-6.00%
6 Month
+49.38%
1 Year
+29.25%
2 Year
+50.13%
5 Year
10 Year

Aashka Hospitals Ltd. Fundamental Ratios

5 years 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 8.87 6.97 15.4 3.76 -2.7
Return on Capital Employed (%) 14.54 11.72 13.12 6.38 0.42
Return on Assets (%) 2.52 2.42 6.58 2.44 -2

Aashka Hospitals Ltd. Balance Sheet

Particulars 6 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 15 24 29 97 94 94
Non Curr. Liab. 26 26 21 17 17 13
Curr. Liab. 13 10 15 15 17 16
Minority Int.
Equity & Liab. 54 60 65 129 128 123
Non Curr. Assets 47 44 51 117 114 109
Curr. Assets 7 16 14 12 14 14
Misc. Exp. not W/O
Total Assets 54 60 65 129 128 123

Aashka Hospitals Ltd. Profit and Loss

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Net Sales 28 27 41 40 19
Other Income 0 0 0 3
Total Income 28 27 41 40 22
Total Expenditure -18 -19 -31 -31 -19
PBIDT 10 9 10 9 3
Interest -6 -5 -3 -3 -3
Depreciation -3 -3 -3 -3 -3
Taxation 0
Exceptional Items
PAT 1 1 4 2 -3
Adjusted EPS 1 1 2 1 -1

Aashka Hospitals Ltd. Cash Flow

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 10 -1 15 -63 4
Cash Fr. Inv. 0 0 -8 -2 0
Cash Fr. Finan. -9 4 -8 63 -2
Net Change 1 3 -1 -2 2
Cash & Cash Eqvt 1 4 3 1 3

Aashka Hospitals Ltd. Shareholding Pattern

6 Qtrs 2021-09 (%) 2022-03 (%) 2022-09 (%) 2023-03 (%) 2023-09 (%) 2024-03 (%)
Promoter 61.28 61.28 61.28 61.28 61.28 61.28
Public 38.72 38.72 38.72 38.72 38.72 38.72
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Aashka Hospitals Ltd. Announcements

Tue, 30 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyAashka Hospitals Ltd
2CIN NO.L85110GJ2012PLC072647
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 19.58
4Highest Credit Rating during the previous FY 0
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Mayank Agarwal
Designation: Company Secretary
EmailId: cs@aashkahospitals.in
Name of the Chief Financial Officer: Lokesh Khandelwal
Designation: Chief Financial Officer
EmailId: csaashkahospital@gmail.com

Date: 30/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Mon, 15 Apr 2024
Compliances - Compliance Certificate For The Period Ended On March 31 2024
We have enclosed the compliance certificate u/r 7(3) of SEBI LODR Regulation for the period ended on March 31 2024
Thu, 11 Apr 2024
Compliance - PCS Certificate U/R 40(10) Of SEBI (LODR) Regulations 2015
We enclose herewith PCS Certificate for Transfer / Transmission / Transposition u/r 40(10) of the SEBI (LODR) Regulations 2015 for the Financial Year ended on March 31 2024

Aashka Hospitals Ltd. Technical Scans

Mon, 06 May 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days

Aashka Hospitals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 367,026.27 1,529.55 +1.4%
Cipla Ltd. 114,924.60 1,423.40 -0.1%
Divi's Laboratories Ltd. 105,128.21 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. 105,108.85 6,293.45 -0.9%
Zydus Lifesciences Ltd. 102,736.49 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. 91,906.55 2,720.45 -0.4%
Mankind Pharma Ltd. 91,490.39 2,286.05 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.21 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 30.99 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 76.02 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.10 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.55 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 61.52 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 52.97 2,286.05 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.88 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 4.44 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 8.07 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.91 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.45 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 10.30 2,286.05 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 0.02 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,286.05 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,286.05 -1.2%

Aashka Hospitals Ltd. FAQ's

What is Aashka Hospitals share price?

Can I buy Aashka Hospitals shares now?

What is the Market Cap of Aashka Hospitals?

What are the key metrics to analyse Aashka Hospitals?

What is the 52 Week High and Low of Aashka Hospitals?

What is the trend of Aashka Hospitals share price?